Pharmaceutical company Qnovia partners with the University of Virginia (UVA) to create inhaled drugs for lung infections, bolstering their development pipeline with assets for pneumonia and biodefense-related pulmonary infections.
Company plans to pursue UK authorization in parallel to approval in the U.S. Qnovia, Inc. ("Qnovia"), a pharma company developing inhaled therapeutics with an initial focus on nicotine replacement